NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

The 99 were randomized to "an intent to crossover group" of whom 64 crossed over, 29 did not and 6 dropped out of the trial. The 92 remaining in the "intend to crossover group" had an mOS that far exceeded the placebo groups and even exceeded the mOS of the DCVax-L trial's treatment group.

Dr. Liau implied in one of her presentations during the Q+A period that the 29 permanent placebos had an mOS that was most likely lower than that of the placebos. It is easy to deduce that the remaining 64 crossovers in the group of 99 had an extremely long mOS.

Conclusion: DCVax-L treatment after progression is very efficaceous and greatly increases the mOS.